Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Therapeutic Advances in Urology|November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolixPatrick Campbell, Georges Gebrael, Arshit Narang, et al.
Prostate Cancer and Prostatic Diseases|January 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapyGeorges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
JAMA Network Open|July 18, 2024
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersChadi Hage Chehade, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|May 2, 2024
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the USVinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
European Urology Oncology|November 9, 2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216Umang Swami, Yeonjung Jo, Arshit Narang, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
Pageof 6